Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B8c7787ae81560c812ed23fb5ce4a73d4> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B8c7787ae81560c812ed23fb5ce4a73d4 NCIT_P378 "NCI" @default.
- B8c7787ae81560c812ed23fb5ce4a73d4 type Axiom @default.
- B8c7787ae81560c812ed23fb5ce4a73d4 annotatedProperty IAO_0000115 @default.
- B8c7787ae81560c812ed23fb5ce4a73d4 annotatedSource NCIT_C78832 @default.
- B8c7787ae81560c812ed23fb5ce4a73d4 annotatedTarget "A whole-cell cancer vaccine, containing human acute myeloid leukemic (AML) blasts that have been genetically engineered to express a B7.1/IIL-2 fusion protein encoded by a self-inactivating lentiviral vector (LV), with potential antineoplastic and immunomodulating activities. Upon administration, LV.IL-2/B7.1-transduced AML blast vaccine RFUSIN2-AML1 may stimulate a host cytotoxic T lymphocyte (CTL) response against AML cells. The single fusion protein encoded by the LV is postsynthetically cleaved to produce biologically active membrane-anchored B7.1 and secreted IL-2 in AML blasts; combined expression of IL-2 and the co-stimulatory molecule B7.1 by AML blasts may increase stimulation of both allogeneic and autologous cytotoxic T cells." @default.